<unk> , sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche. The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach, rash, joint pain, extremity pain, fatigue and nausea.<unk>  regulates inflammation by inhibiting the interleukin-6 (IL-6) receptor, a key mediator of the immune response. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Satralizumab
Caplacizumab
Brolucizumab
Natalizumab
Ixekizumab
Tocilizumab
Benralizumab
Ravulizumab